Home > Neurology > ECTRIMS 2021 > Neuromyelitis Optica Spectrum Disorder (NMOSD) > Long-term efficacy data: inebilizumab for NMOSD

Long-term efficacy data: inebilizumab for NMOSD

Presented By
Prof. Bruce Cree, UCSF Multiple Sclerosis Center, CA, USA
Conference
ECTRIMS 2021
Trial
Phase 3, N-MOmentum
Inebilizumab demonstrated favourable long-term safety and efficacy outcomes for patients with neuromyelitis optica spectrum disorder (NMOSD). Results showed that the risk of attack in NMOSD participants treated with inebilizumab remained low. Moreover, long-term use of inebilizumab did not result in the occurrence of unexpected serious adverse events [1]. Inebilizumab is a humanised anti-CD19 monoclonal antibody depleting B cells, that is approved in the USA for the treatment of NMOSD patients who are seropositive for immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG+) [2]. Prof. Bruce Cree (UCSF Multiple Sclerosis Center, CA, USA) presented the final efficacy and safety data of the 5.5-year follow-up, open-label extension (OLE) period of the randomised-controlled, phase 2/3 N-MOmentum trial (NCT02200770). NMOSD AQP4+ patients (n=230) were ra...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on